This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The 5 Dumbest Things on Wall Street This Week: June 1

5. Vertex Shall Meet Twain

Forgive us Mark Twain, but when it comes to Vertex Pharmaceuticals (VRTX - Get Report) recent meltdown, it's less about "lies, damn lies and statistics" than a case of stupidity, damn stupidity and statistics.

Shares of Vertex tumbled 11% Tuesday, after the high-flying biotech released corrected data involving its cystic fibrosis treatments that drastically reduced the number of patients who showed better lung function. Back on May 7, the company's stock shot up 55% after Vertex released a far rosier set of figures, which at the time inflated investor hopes that Vertex was indeed close to introducing an effective, not to mention profitable, therapy to fight the life-threatening genetic disorder.

Oh lord, that's just ridiculous. To paraphrase the great Twain once again: What a bunch of jackasses!

Or maybe it was Samuel Clemens who said that line, we aren't quite sure. We always get those two guys mixed up.

Seriously though, we are quite certain that Vertex is trying to shift the blame for the statistical screw-up that sent its stock on its own version of a wild Mississippi river ride. The company swears the error was the result of a vendor's misinterpretation of the data, not its own.

"This mistake is very disappointing," said CEO Jeffrey Leiden on a conference call with analysts. "It's unacceptable to us."

Give us a break Jeffrey. What's really unacceptable is that fact that you didn't double-check the denominator yourself before going public with the findings.

So the next time you have market-moving news to deliver, we suggest you follow Twain's timeless advice and "get your facts first and then you can distort them as much as you wish." Not the other way around.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CHK $15.45 0.00%
JPM $62.84 0.00%
PBY $8.60 0.00%
VRTX $125.07 0.00%
AAPL $124.75 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs